Sudeep Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹197 Cr +20.9% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
SP

Sudeep Pharma Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Sudeep Pharma Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹163Cr
+9.4% YoY
+30.4% QoQ
Net profit
₹47Cr
−4.1% YoY
+51.6% QoQ
Margin
34%
−9 pp YoY
−1 pp QoQ
Price₹1,112
Market cap₹10.8K Cr
P/E59.3

The short version

FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.

From Sudeep Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY '26 growth expected at approximately 26%, sustained for the full year.
  • Significant growth anticipated in Q3 FY '26, especially in the US market, post-tariff clarity.
  • NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area.
  • NSS capacity utilization currently ~35%, with plans to scale volumes notably by FY '27.
  • New Greenfield facility (51,200 metric tons capacity) expected commissioning Q4 FY '26; first meaningful production from this site expected in H2 FY '27 and predominantly FY '28.
  • Current overall manufacturing utilization near 50%, expected to increase with new capacity and approvals over next 2-3 years.

2 more points from Sudeep Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Acquired a 20-acre land in Dahej for new manufacturing facility.
  • Phase one capex for Dahej site: ~INR 220 crores (includes land and development) for 25,000 tons capacity.
  • Infrastructure being built to support phase two, doubling capacity to 50,000 tons.
  • Long-term goal to scale plant to 100,000 tons for battery-grade iron phosphate.
  • Total expected capex to reach ~INR 500 crores over next few years.
  • Existing pilot plant producing 200 kgs/day; samples supplied to 36+ customers.
  • Capacity enhancement planned on existing food grade iron phosphate line to meet early demand before Dahej plant operational.
  • Greenfield capex of INR 150 crores for 51,200 MT capacity, with INR 120 crores spent by Sept '25; balance INR 20-30 crores to be spent by March '26.

2 more points from Sudeep Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company anticipates a strong Q3 FY26 due to delayed order book recognition in Q2, especially from the US market impacted by tariff uncertainties.
  • NSS, acquired in May 2025, has a significant project pipeline in Europe and global markets to expand its infant and clinical nutrition offerings.
  • NSS is currently operating at approximately 35% capacity utilization, with plans to scale up through leveraging Sudeep Pharma’s global customer base.
  • Campaign orders for large pharma and nutrition companies contribute significantly but are irregular, causing quarterly fluctuations in order volumes.

2 more points from Sudeep Pharma Ltd's call on order book

Create a free account to keep reading this call

Sudeep Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sudeep Pharma Ltd Q2 FY26 results — key figures

Sudeep Pharma Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue163149+9.4%125+30.4%
Operating profit (EBITDA)5563-12.7%44+25%
Operating margin34%43%-9 pp35%-1 pp
Profit before tax6062-3.2%44+36.4%
Net profit (PAT)4749-4.1%31+51.6%
EPS (₹)4.715.80-18.8%3.17+48.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹197 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudeep Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudeep Pharma Ltd Q2 FY26 results?

FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.

What is Sudeep Pharma Ltd share price analysis?

Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudeep Pharma Ltd planning capital expenditure?

Acquired a 20-acre land in Dahej for new manufacturing facility.

Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.